Streetbeat News

TRML

Tourmaline Bio, Inc.

https://www.tourmalinebio.com

Industry

Biotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Open

18.68

Mkt cap

468M

Volume

628K

High

18.85

P/E Ratio

-6.32

52-wk high

45.55

Low

17.40

Div yield

N/A

52-wk low

11.87

Tourmaline Bio has released its Q4 and full-year 2024 financial results, highlighting the over-enrollment of its Phase 2 TRANQUILITY trial and the strengthening of its Cardiovascular Scientific Advisory Board.

Portfolio Pulse from

March 13, 2025 | 11:45 am

Tourmaline Bio, Inc. has appointed Dr. Paul M. Ridker to its Cardiovascular Scientific Advisory Board, enhancing its expertise in developing transformative medicines for immune and inflammatory diseases.

Portfolio Pulse from

January 10, 2025 | 12:45 pm

Tourmaline Bio, Inc. (NASDAQ: TRML) announced key updates at its Investor Day, including surpassing enrollment targets for its Phase 2 TRANQUILITY trial and nominating a new cardiovascular indication for its drug pacibekitug.

Portfolio Pulse from

December 10, 2024 | 1:45 pm

Tourmaline Bio, Inc. (NASDAQ: TRML) will host a virtual Investor Day on December 10, 2024, featuring presentations from its leadership and Dr. Marc Bonaca. The event aims to provide insights into the company's progress in developing medicines for immune and inflammatory diseases.

Portfolio Pulse from

November 14, 2024 | 12:45 pm

Tourmaline Bio, Inc. reported its Q3 2024 financial results, highlighting a cash position of $314.4 million, which extends its runway into 2027. The company is on track to release Phase 2 trial data in 2025 and has formed a Cardiovascular Scientific Advisory Board.

Portfolio Pulse from

November 07, 2024 | 12:45 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Tourmaline Bio (NASDAQ:TRML) and maintained a price target of $48.